Published in Mult Scler on December 22, 2009
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int (2013) 0.93
Oligoclonal bands in tears. Mult Scler (2010) 0.77
Evaluation of semi-automatic image analysis tools for cerebrospinal fluid electrophoresis of IgG oligoclonal bands. Pract Lab Med (2017) 0.75
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med (2010) 4.08
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol (2007) 3.81
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) (2004) 2.54
Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke (2003) 2.31
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J (2011) 1.93
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol (2010) 1.78
A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol (2010) 1.77
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol (2011) 1.69
High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J (2005) 1.64
Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol (2009) 1.51
Long-term follow-up of acute partial transverse myelitis. Arch Neurol (2012) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain (2010) 1.42
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry (2012) 1.42
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain (2004) 1.31
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol (2010) 1.28
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler (2013) 1.25
Stroke in the very old: incidence, risk factors, clinical features, outcomes and access to resources--a 22-year population-based study. Cerebrovasc Dis (2009) 1.23
A benign form of neuromyelitis optica: does it exist? Arch Neurol (2011) 1.21
Optical coherence tomography in neuromyelitis optica. Arch Neurol (2008) 1.20
Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler (2011) 1.19
Stable stroke incidence rates but improved case-fatality in Dijon, France, from 1985 to 2004. Stroke (2006) 1.18
Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness. BMC Infect Dis (2010) 1.18
New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Lett (2005) 1.15
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain (2011) 1.11
Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain (2013) 1.11
Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol (2005) 1.11
Geographic variations of multiple sclerosis in France. Brain (2010) 1.10
One can prevent post-partum MS relapses by exclusive breast feeding: no. Mult Scler (2013) 1.09
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler (2008) 1.08
Clinical spectrum of movement disorders after stroke in childhood and adulthood. Eur Neurol (2012) 1.06
A mutation that creates a pseudoexon in SOD1 causes familial ALS. Ann Hum Genet (2009) 1.06
Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry (2007) 1.05
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler (2013) 1.03
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci (2003) 1.00
Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene. Ophthalmology (2010) 0.99
Trends in incidence, risk factors, and survival in symptomatic lacunar stroke in Dijon, France, from 1989 to 2006: a population-based study. Stroke (2008) 0.99
Prevalence of early dementia after first-ever stroke: a 24-year population-based study. Stroke (2011) 0.99
NIPA1 (SPG6) mutations are a rare cause of autosomal dominant spastic paraplegia in Europe. Neurogenetics (2007) 0.99
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci (2010) 0.99
Uveitis associated with multiple sclerosis. Mult Scler (2008) 0.98
Epidemiology of stroke in Europe: geographic and environmental differences. J Neurol Sci (2007) 0.97
Cognitive function in radiologically isolated syndrome. Mult Scler (2010) 0.97
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol (2012) 0.97
Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol (2012) 0.96
Cognitive functions in neuromyelitis optica. Arch Neurol (2008) 0.96
European validation of a standardized clinical description of multiple sclerosis. J Neurol (2004) 0.96
Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J (2009) 0.96
Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol (2010) 0.96
A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: clinical and pathological findings. Neuromuscul Disord (2008) 0.95
Optical coherence tomography in clinically isolated syndrome: no evidence of subclinical retinal axonal loss. Arch Neurol (2009) 0.95
Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol (2007) 0.95
Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol (2011) 0.94
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol (2013) 0.94
Enterovirus meningitis in adults in 1999-2000 and evaluation of clinical management. J Med Virol (2002) 0.94
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma (2008) 0.94
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology (2013) 0.93
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol (2010) 0.93
The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin (2007) 0.92
The natural history of multiple sclerosis with childhood onset. Clin Neurol Neurosurg (2008) 0.92
Autoantibodies against alpha-fodrin in Sjögren's syndrome with neurological manifestations. J Rheumatol (2004) 0.92
Involuntary masturbation and hemiballismus after bilateral anterior cerebral artery infarction. Clin Neurol Neurosurg (2007) 0.91
Comorbidities at multiple sclerosis diagnosis. J Neurol (2013) 0.90
Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. Brain (2009) 0.90